CDK4/6 Inhibitors

Stichwort: CDK4/6 Inhibitors

The on-demand video of the webinar “CDK4/6 Inhibition in Early and Advanced Breast Cancer – Recent data and controversies 2024“ is now available!

14.11.2024

The virtual continuing education event “CDK4/6 Inhibition in Early and Advanced Breast Cancer – Recent Data and Controversies 2024” took place on Wednesday, October 30th, 2024, from 5:30 to 7:30 pm CET. A total of 116 participants from 15 countries joined the webinar, which was moderated by ABCSG President Michael Gnant.

weiter

The on-demand video of the webinar „CDK4/6 inhibition in early breast cancer – Recent data and controversies?“ is now available!

22.11.2023

The virtual continuing education event “CDK4/6 inhibition in early breast cancer – Recent data and controversies?” took place on Wednesday, November 8th, 2023 (05:30 – 07:00 pm, CET). A total of 104 participants from 13 countries participated in the webinar.

weiter

CDK4/6 inhibition in early breast cancer – Recent data and controversies?

29.08.2023

Datum	08.11.2023
Ort:	virtual

In this international ABCSG webinar that is co-sponsored by EliLilly and Novartis we will present and discuss the most recent data of the pivotal adjuvant CDK4/6 studies monarchE and NATALEE.

weiter

Paradigm shift: a changing CDK4/6 inhibitor treatment landscape – NOW ONLINE!

12.07.2023

Datum	14.09.2023
Ort:	virtual

CDK4/6 inhibitors – The big picture: what do we know so far?
Earlier than ever: defining the role of adjuvant CDK4/6 inhibition
Breaking new grounds: what’s next?

weiter

Die ABCSG-Ergebnisse am ASCO 2022

10.06.2022

Wie angekündigt, wurde die Österreich am diesjährigen American Society of Clinical Oncology (ASCO) Meeting, das von 03.-07. Juni in Chicago stattfand, durch Univ.-Prof. Dr. Michael Gnant und Assoz. Prof. Priv.-Doz- Dr. Georg Pfeiler vertreten.

weiter

The Changing Treatment Landscape of CDK4/6 Inhibitors
Moving From Late to Early Stages – 09 May 2022

08.04.2022

Datum	May 09, 2022
Ort:	virtual

Cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged as an appealing targeted cancer therapy of patients with hormone receptor-positive breast cancer. Prior to the availability of CDK4/6 inhibitors, standard first-line therapy for patients with HR+/HER2- mBC was single-agent endocrine therapy.

weiter